Applied BioCode

Applied BioCode is a research and development company headquartered in Los Angeles, California. With 63 employees, the company generates $10.3 million in annual revenue. Applied BioCode specializes in developing, manufacturing, and commercializing multiplex diagnostic testing products. The company's core technology is Barcoded Magnetic Beads (BMB), a novel bio-inspired platform that utilizes digital barcodes coupled with immunochemistry and molecular probes. This allows for the precise identification of a high number (4,096) of biological targets with exceptional accuracy. Applied BioCode focuses on the molecular diagnostic infectious disease market, offering assays that detect pathogens for gastrointestinal, respiratory, and other high-value diseases. Applied BioCode's products have received regulatory approvals, including FDA Clearance for the BioCode® MDx-3000 system with Gastrointestinal Pathogen Panel (GPP) and Respiratory Pathogen Panel (RPP) assays. The GPP has also received CE-Mark certification for use in European countries. In response to the COVID-19 pandemic, the company developed a BioCode® SARS-CoV-2 Assay authorized by the FDA under Emergency Use Authorization (EUA). For more information about Applied BioCode and its products, visit their website at apbiocode.com.